Thermo Fisher Scientific Bioproduction Articles
-
Improving Workflow Automation And Process Control
10/17/2022
Learn about optimizing your T cell manufacturing process and reducing operating costs with rocking bioreactors using CTS OpTmizer T Cell Expansion SFM.
-
Impact Of Media, Stirred-Tank Bioreactors On Cell Therapy Manufacturing
10/14/2022
Rocking motion bioreactors have long been the mainstay in T-cell therapy, but stirred-tank bioreactors have garnered a lot of excitement because of several potential advantages.
-
Deliver Product Quality, Enhance Productivity In CHO-K1, CHO-S Cells
6/20/2022
Early identification of a robust, commercially available, optimized platform medium and cell line–specific feed could be the keys to achieving strong productivity and delivering product to market more rapidly.
-
Improve Productivity In CHO-K1, CHO-S, And DG44 Cells
4/18/2022
This commercially available platform can enhance process productivity and reduce development time, thereby enabling potential reductions in manufacturing costs and accelerating time-to-market.
-
Single-Use Solutions For Research And Process Development
4/12/2022
Can supply chain assurance be maintained while offering an array of possibilities to achieve complex process designs? Learn if you could benefit from a modularized, standardized single-use manifold design.
-
Reducing Risk During CAR T Cell Therapy Development And Manufacture
1/26/2022
It is essential to identify potential areas for optimization early in CAR T cell therapy development—particularly with respect to equipment, reagents, and analytics.
-
Streamlining Upstream Plasmid DNA Manufacturing
12/9/2021
Here we will discuss the scalable process workflow solutions available from initial R&D investment to clinical testing and commercialization.
-
Diploid Serum-Reduced Medium System Supports Viral Production
10/21/2021
Results demonstrate that the system can enable vaccine manufacturers to reduce the use of FBS while achieving potential increases in viral specific productivity with diploid cells.
-
Reduce Or Eliminate Serum Use In Vaccine Production
10/21/2021
The use of this Diploid Growth Serum-Reduced Medium (SRM) helps vaccine manufacturers using diploid cells meet their production forecasts while reducing production costs and serum use.
-
Optimize Allogeneic Workflow, Cell Proliferation
8/17/2021
This application note outlines the capabilities of CTS OpTmizer Pro SFM compared with a control medium in both diseased patients’ and healthy donors’ cells.